Literature DB >> 29629530

Paraneoplastic Neuromyelitis Optica Associated with Lung Adenocarcinoma in a Young Woman.

Kyoung Won Baik1, Se Hoon Kim2, Ha Young Shin3.   

Abstract

Entities:  

Year:  2018        PMID： 29629530      PMCID： PMC5897211          DOI： 10.3988/jcn.2018.14.2.246

Source DB:  PubMed          Journal:  J Clin Neurol        ISSN： 1738-6586            Impact factor:   3.077


× No keyword cloud information.
  7 in total

1.  A possible paraneoplastic neuromyelitis optica associated with lung cancer.

Authors:  Giuseppe De Santis; Luisa Caniatti; Alessandro De Vito; Riccardo De Gennaro; Enrico Granieri; Maria Rosaria Tola
Journal:  Neurol Sci       Date:  2009-06-30       Impact factor: 3.307

2.  Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.

Authors:  Raffaele Iorio; Guido Rindi; Carmen Erra; Valentina Damato; Michela Ferilli; Mario Sabatelli
Journal:  Mult Scler       Date:  2015-02-25       Impact factor: 6.312

3.  Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

Authors:  Marina Frasquet; Luis Bataller; Estefanía Torres-Vega; María Durán-Moreno; José M García-Verdugo; Teresa Sevilla; Salvador Rivas; Francisco Pérez-Miralles; María Simó-Castelló; Bonaventura Casanova
Journal:  J Neuroimmunol       Date:  2013-07-27       Impact factor: 3.478

4.  Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4.

Authors:  Michelle Figueroa; Yong Guo; Alexandros Tselis; Sean J Pittock; Vanda A Lennon; Claudia F Lucchinetti; Robert P Lisak
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

5.  A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody.

Authors:  Sabine Mueller; Dena B Dubal; S Andrew Josephson
Journal:  Nat Clin Pract Neurol       Date:  2008-03-04

6.  Loss of aquaporin-4 expression and putative function in non-small cell lung cancer.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Esther Herpel; Anita Pathil; Hans Hoffmann; Philipp A Schnabel; Christian Bender; Andreas Buness; Peter Schirmacher; Ruprecht Kuner
Journal:  BMC Cancer       Date:  2011-05-06       Impact factor: 4.430

7.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910
  7 in total
  5 in total

1.  Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder.

Authors:  Pilar Carrillo; Teresa Gorría; Daniel Santana; Maria Sepulveda; Iban Aldecoa; Blanca Gonzalez-Farré; Esther Sanfeliu; Eduard Mension; Isaac Cebrecos; Olga Martínez-Saez; Imma Alonso; Albert Saiz
Journal:  Biomed Hub       Date:  2022-01-31

2.  A Case of Late-Onset Neuromyelitis Optica Spectrum Disorder Associated With Cryptogenic Organizing Pneumonia.

Authors:  Seung Won Ra; Soyeoun Lim; Hee Jeong Cha; Sunyoung Kim
Journal:  Clin Med Insights Case Rep       Date:  2022-05-18

Review 3.  Pain Symptoms in Optic Neuritis.

Authors:  Xiayin Yang; Xuefen Li; Mengying Lai; Jincui Wang; Shaoying Tan; Henry Ho-Lung Chan
Journal:  Front Pain Res (Lausanne)       Date:  2022-04-14

4.  Lung adenocarcinoma-related target gene prediction and drug repositioning.

Authors:  Rui Xuan Huang; Damrongrat Siriwanna; William C Cho; Tsz Kin Wan; Yan Rong Du; Adam N Bennett; Qian Echo He; Jun Dong Liu; Xiao Tai Huang; Kei Hang Katie Chan
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

Review 5.  AQP4-IgG positive paraneoplastic NMOSD: A case report and review.

Authors:  Manqiu Ding; Yue Lang; Li Cui
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.